retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Efficacy and safety of retatrutide, a GIP, GLP-1, and receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Triple Agonism Based Therapies for

Description

Even intravenous administration of GLP-1 at a physiological postprandial dose of 0.3 pmol/kg/min significantly slowed the rate of gastric emptying in healthy subjects, bringing them into a state of gastroparesis (Little et al., 2006)

Weight regain is very common after stopping a GLP-1on average, up to two-thirds of the lost weight is regained within one year

Future Developments in GLP-1 Research Scientists continue studying new applications for GLP-1 medications

doi:10.1056/NEJMoa1307684 100

Metabolic liver disease Real-world registry data from Sweden, Denmark, and Norway (20072020) showed a reduced incidence of acute liver events in individuals with type 2 diabetes initiating GLP-1RA therapy compared to dipeptidyl peptidase 4 (DPP-4) inhibitors